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Abstract: Uterine fibroids are the most common benign tumors of the female genital tract. 
The management of symptomatic fibroids has traditionally been surgical; however, alternative 
pharmacological approaches have been proposed to control symptoms. To date, gonadotropin-
releasing hormone analogs are the only available drugs for the preoperative treatment of fibroids. 
However, the US Food and Drug Administration recently authorized ulipristal acetate (UPA), an 
oral selective progesterone-receptor modulator, for the same indication. UPA is a new, effective, 
and well-tolerated option for the preoperative treatment of moderate and severe symptoms of 
uterine fibroids in women of reproductive age. According to clinical data, UPA shows several 
advantages: it is faster than leuprolide in reducing the fibroid-associated bleeding, it signifi-
cantly improves hemoglobin and hematocrit levels in anemic patients, and it grants a significant 
reduction in the size of fibroids, which lasts for at least 6 months after the end of the treatment. 
Furthermore, UPA displays a better tolerability profile when compared to leuprolide; in fact, it 
keeps estradiol levels at mid follicular phase range, thereby reducing the incidence of hot flushes 
and exerting no impact on bone turnover. On the grounds of this evidence, the administration of 
5 mg/day ulipristal acetate for 3 months is suggested for different patient categories and allows 
for planning a treatment strategy tailored to meet an individual patient’s needs.
Keywords: ulipristal acetate, uterine fibroids, myomas, selective progesterone-receptor modula-
tor, medical treatment of uterine fibroids
Introduction
Uterine fibroids (or myomas) are monoclonal tumors of the smooth muscle cells of 
the uterus. They are considered the most common benign tumors of the female genital 
tract, as they are clinically apparent in up to 25% of women irrespective of their age. 
Moreover, they occur in up to 30%–40% of women over the age of 40.1 The reported 
incidence ranges from 30% to 70% in premenopausal women and increases with age.2 
Both the etiology and biology of uterine fibroids are poorly understood, but strong 
evidence supports the role of hormonal factors (estrogens and progestogens) in favor-
ing tumor growth.3–4 Myomas rarely appear before menarche5 and frequently regress 
after menopause. Several risk factors have been identified, such as ethnicity, nulliparity, 
genetics, and hormonal factors. Symptomatic women typically suffer from abnormal 
uterine bleeding, which is usually heavy and prolonged and hence results in anemia. 
Moreover, affected women frequently report dysmenorrhea, dyspareunia, non-cyclic 
pelvic pain and urinary symptoms (ie, bladder tenesmus). As one can easily infer, uter-
ine fibroids can negatively affect a woman’s quality of life and work productivity. In a 
recent paper, 53.7% women reported a dramatic decline in their quality of life, due to a 





general impairment in sexual life (42.9%), work productivity 
(27.7%), as well as family and daily life (27.2%).6
This review analyses clinical studies on the use of ulip-
ristal acetate (UPA), an oral selective progesterone modulator 
(SPRM), for the pharmacological management of uterine 
fibroids. UPA may be a new, effective, and well-tolerated 
option for the preoperative treatment of moderate and severe 
symptoms in reproductive age women.
Pharmacological management  
of uterine fibroids
The management of symptomatic fibroids has traditionally 
been surgical; however, alternative pharmacological treat-
ments have been proposed to control symptoms. The choice 
of the appropriate therapeutic approach depends on several 
factors, including: age, parity, childbearing aspirations, 
extent and severity of symptoms, size, number and location of 
myomas, risk of malignancy, and proximity to menopause.
Oral combined contraceptive pills are often used to con-
trol menorrhagia and dysmenorrhea. However, combined 
pills may cause an increase in the size of myomas.6
Besides exerting a direct anti-estrogenic effect at the 
cellular level, progestational agents may also inhibit gonado-
tropin secretion and suppress ovarian function, thereby 
producing an additional hypoestrogenic effect.6 Danazol is 
chemically related to 17-ethinyl testosterone, which creates 
a hormonal milieu characterized by high androgen and low 
estrogen levels. Therefore, it induces endometrial hypotrophy 
and enhances the shrinkage of the fibroids. However, several 
side effects have been described, including acne, hirsutism, 
weight gain, irritability, musculoskeletal pain, hot flushes, and 
breast atrophy. In addition to that, no randomized controlled 
trial has proven that the benefits of danazol outweigh its risks, 
when treating uterine fibroids.7 The use of a levonorgestrel 
intrauterine device (LNG-IUS) has been associated with a 
reduction in menstrual blood loss in women with uterine 
myomas, but its effect on the size of uterine myoma is still 
debated.8 LNG-IUS is contraindicated in the case of fibroid-
associated severe distortion of the uterine cavity (LNG-IUS 
SmPC), because of the high expulsion rate.8–10
Furthermore, gonadotropin-releasing hormone analogs 
(GnRHa) proved to be successful both as a conserva-
tive treatment and as a preoperative therapy of myomas. 
They are highly effective in reducing both the symptoms 
(bleeding, anemia, and abdominal pain) and the volume of 
fibroids.11,12 However, these effects are transient and the myo-
mas usually return to pre-therapy size within a few months 
of discontinuation.  Preoperative GnRHa treatment before 
myomectomy decreases the size and vascularity of the myoma 
but may make the capsule more fibrous and hence difficult to 
resect. Furthermore, some of the treatment-associated adverse 
effects (menopausal symptoms, osteoporosis, and pelvic pain) 
could benefit from a hormonal add-back although it may 
reduce the beneficial effects of GnRHa on myoma size.13
Recently, the potential therapeutic role of non-steroidal 
aromatase inhibitors has been suggested.14 Aromatase 
inhibitors appear as effective as GnRHa, and have fewer 
side effects. However, the use of these drugs is presently 
restricted to infertile women due to the unknown influence 
of body mass index on treatment efficacy, the sparse data on 
subsequent reproductive outcome, and the absence of long-
term follow-up data.15
Mechanism of action of ulipristal  
acetate in the treatment  
of uterine fibroids
In uterine fibroids estrogen and progesterone receptors are 
expressed at higher levels than in normal myometrium.16 
The influence of estrogen on fibroid growth is well-known, 
while the role of progesterone and the progesterone-receptor 
(PR), as well as ovarian steroids has emerged only recently. 
In fact, biochemical and clinical studies have suggested that 
the former may enhance proliferative activity in fibroids and 
the latter may influence fibroid growth.17 These observations 
have inspired studies testing the efficacy of anti-progestins 
in the medical management of uterine fibroids.
Selective progesterone-receptor modulators (SPRMs) are 
a new class of PR ligands displaying tissue-selective agonist/
antagonist/mixed activity on target cells.18 UPA is an orally 
active synthetic SPRM, characterized by a tissue-specific 
partial progesterone antagonist effect.19
Progesterone normally promotes fibroid growth in two 
ways: on the one hand, it up regulates epidermal growth factor 
(EGF) and Bcl-2 gene, on the other hand it down regulates 
the tumor necrosis factor gene (TNF). UPA, as a progesterone 
antagonist, inhibits the proliferation of leiomyoma cells and 
induces apoptosis by increasing cleaved caspase-3 expres-
sion and decreasing Bcl-2 expression.17 Moreover, UPA 
down regulates the expression of angiogenic growth factors, 
such as vascular endothelial growth factor (VEGF) and their 
receptors. Thus, it suppresses neo-vascularization, cell pro-
liferation, and survival in leiomyoma cells but not in normal 
myometrial cells.20 Additionally, UPA increases the expres-
sion of matrix metalloproteinases (MMPs) and decreases the 
expression of tissue inhibitor of metalloproteinases (TIMPs) 
and collagens in cultured fibroid cells. Thus, UPA may impair 
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fibroid tissue integrity by reducing the deposition of collagen 
in the extracellular spaces.21
Besides, UPA acts on the hypothalamic–pituitary–ovarian 
axis, thereby inhibiting or delaying ovulation and inducing 
amenorrhea. Since UPA does not alter basal levels of luteiniz-
ing hormone and follicle stimulating hormone, estradiol 
levels remain within the physiological mid-follicular range 
(60–150 pg/mL) and hence the symptoms of estrogen depri-
vation do not occur. However, UPA induces amenorrhea in 
most women due to its interaction with endometrial proges-
terone receptors.19,20 In conclusion, UPA selectively acts on 
uterine fibroids and their related symptoms and represents a 
promising new option for the pre-surgical medical treatment 
of uterine fibroids.
Therapeutic efficacy  
of ulipristal acetate
The administration of 5–10 mg/day UPA for up to 3 months 
has been proposed as a preoperative treatment for moderate 
to severe fibroid-associated symptoms. Its clinical efficacy 
and tolerability profile have been the object of two random-
ized, double-blind, multinational, Phase III trials (Table 1). 
PEARL I (PGL4001 versus placebo in uterine myomas) 
has set oral UPA (5 or 10 mg/day) against placebo,22 while 
Table 1 Main clinical outcomes of PeARL i and PeARL ii studies22,23
Endpoint Placebo UPA 5 mg UPA 10 mg Conclusion
PEARL I
Control of uterine bleeding (PBAC score  
,75 at week 13)
19% 91% 92% Superiority of UPA versus placebo
Correction of anemia (hemoglobin .12 mg/dL  
at week 13)
77.1% 85.3% 89.4% Superiority of UPA versus placebo
Shrinkage of fibroids (median % of volume  
reduction from basal at week 13)
+3% -21.2% -12.3% Superiority of UPA versus placebo
Pain reduction -2.5 -5.0 -5.6 Superiority of UPA versus placebo
Adverse events leading to discontinuation  
of study drug
2% 1% 1%
Endpoint LA 3.75 mg UPA 5 mg UPA 10 mg Conclusion
PEARL II
Control of uterine bleeding  
(PBAC score ,75 at week 13)
89% 90% 98% Non inferiority of UPA versus LA
Shrinkage of fibroids (median % of volume  
reduction from baseline at week 13)
-53% -36% -42% Not significant differences 
between UPA and LA
Pain reduction -5.5 -5.0 -6.0 Not significant differences 
between UPA and LA
Adverse events leading to discontinuation  
of study drug
6% 1% 2%
Hot flushes (moderate to severe hot  
flushes at week 13)
40% 11% 10% Superiority of the tolerability 
profile of UPA versus LA
estradiol levels at week 13 25 pg/mL 64 pg/mL 60.5 pg/mL Superiority of the tolerability 
profile of UPA versus LA
Abbreviations: UPA, ulipristal acetate; PBAC, pictorial bleeding assessment chart; LA, leuprolide acetate.
PEARL II (PGL4001 versus GnRHa in uterine myomas) has 
compared UPA (5–10 mg/day) with the GnRHa leuprolide 
acetate (LA; one-monthly intramuscular injection, 3.75 mg).23 
In both trials, treatment was started on one of the first 4 days 
of menstruation and was continued for 13 weeks.
In the PEARL I trial, patients were randomized to receive 
UPA 5 mg/day (96 women), or UPA 10 mg/day (98 women), 
or placebo (48 women). All patients received 80 mg iron sup-
plementation once daily during the active-treatment phase. 
Inclusion criteria were: premenopausal women between 
18 and 50 years old with myomatous uterus, menorrhagia, 
and anemia. The uterus had to be equivalent in size to a preg-
nant uterus of #16 weeks gestation, with at least one fibroid 
of 3 cm or more in diameter, but with no fibroid exceed-
ing 10 cm diameter under magnetic resonance imaging. 
 Fibroid-associated uterine bleeding was measured by the 
Pictorial Bleeding Assessment Chart (PBAC score)24 and 
values .100 on days 1–8 of menstruation were considered 
eligible for inclusion. The presence of fibroid related anemia 
(hemoglobin level #10.2 g/dL without macrocytosis) was 
another inclusion criterion. The primary endpoints were the 
efficacy of UPA versus placebo in controlling excessive 
bleeding (PBAC ,75) and the reduction of fibroid volume at 
week 13. Secondary endpoints included amenorrhea, time 





required to control bleeding, reduction in uterine volume, 
changes in hemoglobin values, pain, and quality of life. The 
latter were tested with a questionnaire assessing discomfort 
associated with uterine fibroids. Finally, the work assessed 
the overall tolerability of UPA considering treatment related 
adverse events and endometrial changes.22
The PEARL II trial analyzed the efficacy and tolerability 
of UPA in 307 patients with symptomatic fibroids, by compar-
ing it with a GnRHa, LA. Patients were randomized to UPA 
5 or 10 mg once daily (97 and 103 women, respectively) or 
to a once-monthly intramuscular injection of LA 3.75 mg 
(101 women). Inclusion criteria were similar to those of the 
previous study, except for anemia, that was not required. 
The study meant to demonstrate that UPA is not inferior to 
LA in reducing the uterine bleeding, as a primary endpoint. 
Moreover, the trial was aimed at proving the better tolerability 
profile of UPA in terms of estradiol levels and incidence of 
hot flushes. Secondary endpoints included bleeding pattern 
(consecutive 28-day PBAC scores), amenorrhea, changes 
from baseline in fibroid and uterine volume, pain, and qual-
ity of life tested with a questionnaire assessing discomfort 
associated with uterine fibroids.23
In the PEARL I trial, uterine bleeding was controlled 
at week 13 in 91%, 92%, and 19% women receiving UPA 
(5 mg), UPA (10 mg), and placebo, respectively. Thus, the 
PEARL I trial demonstrated the effectiveness of UPA in 
controlling uterine bleeding.22 Furthermore, the PEARL II 
trial proved that UPA is not inferior to GnRHa. In fact, uter-
ine bleeding was controlled at week 13 in 90%, 98%, and 
89% of women receiving UPA (5 mg), UPA (10 mg), and 
LA, respectively. 23
An important clinical feature is the time needed to con-
trol bleeding. In PEARL I bleeding control was achieved on 
day 8 in .75% patients receiving 5 or 10 mg UPA versus 
6% being administered placebo. Amenorrhea occurred within 
the first 10 days of treatment in approximately half of the 
women treated with 5 mg UPA and 70% treated with 10 mg 
UPA.22 In PEARL II, 85% women receiving 5 mg of UPA 
and 60% receiving LA achieved bleeding control on day 10. 
Thus, UPA allowed a quicker control of uterine bleeding 
when compared to LA. The median time required to achieve 
amenorrhea in the two groups was 7 and 21 days, while recur-
rence of menstruation after treatment withdrawal required 
30–34 days in the UPA group and 43 days in the LA group, 
respectively.23
Such a quick effect has major advantages in anemic 
patients. In fact, in PEARL I, UPA administration was 
associated with higher hemoglobin and hematocrit levels 
than placebo, even though all patients received the same 
iron supplementation. In the 13th week, hemoglobin levels 
were .12 g/dL in 89.4%, 85.3%, and 77.1% women receiving 
5 mg UPA, 10 mg UPA, and placebo, respectively.
The shrinkage of fibroids was the primary endpoint in 
PEARL I and one of the secondary endpoints in PEARL 
II. The former proved that 5 mg or 10 mg UPA allowed a 
greater reduction in fibroid size, as measured at week 13, 
than placebo (-21%, -12%, and +3% respectively).22 In 
PEARL II, the reduction in the volume of the three largest 
uterine fibroids was comparable between the groups; how-
ever, the effect of UPA lasted longer. Women who did not 
undergo fibroid surgery were examined after 38 weeks of 
follow-up: the decrease in total fibroid volume was retained 
in UPA recipients, whereas it went back to the baseline in a 
high proportion of patients receiving LA.23
In the PEARL I trial, the administration of UPA 10 mg 
was more efficient for pain reduction than placebo (-5.6 
versus -2.5), while PEARL II failed to uncover any sig-
nificant difference between the three groups at the end of 
treatment (-5.0, -6.0, and -5.5, respectively). Both trials 
demonstrated an overall improvement in the quality of life 
of symptomatic women treated with UPA.
As we can infer from the results of both trials, the effect 
of a daily administration of 5 mg UPA does not differ sig-
nificantly from daily administration of 10 mg UPA. Thus, the 
proposed dosage was set at 5 mg/day, which was defined as 
the minimum effective dose of the drug.22,23
Tolerability profile
Both PEARL trials have assessed UPA tolerability. The most 
frequent adverse events were amenorrhea (even though it 
represents a target to reach rather than an adverse effect in 
the case of uterine fibroids), headache, flushes, dizziness, 
discomfort, and tenderness in the breast. In all, 94% of 
patients reported adverse effects, describing their intensity 
as moderate, moreover such events resolved spontaneously 
at the end of treatment. As demonstrated by PEARL I, the 
choice of the drug did not influence the occurrence rate of 
any adverse events reported.22 Furthermore, the incidence 
of adverse events leading to drug discontinuation was 1%, 
1%, and 2% in the groups treated with UPA 5 mg, UPA 
10 mg, and placebo, respectively. Similar rates were reported 
in PEARL II: 1%, 2%, and 6% patients treated with UPA 
5 mg, UPA 10 mg, and LA, respectively, discontinued drug 
administration.23
PEARL II assessed estradiol levels and incidence of 
hot flushes as the primary endpoint. The incidence of hot 
flushes was recorded at week 13: UPA allowed a significant 
reduction in the incidence of moderate to severe hot flushes 
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(11% versus 40%).23 In women receiving UPA, plasma 
estradiol levels were steadily within the midfollicular range 
(60–150 pg/mL), as confirmed by both trials. On the contrary, 
LA was associated to significantly lower estradiol levels 
(25 pg/mL versus 64 pg/mL), resulting in the occurrence of 
menopausal symptoms and bone loss.22,23
Effects of ulipristal acetate  
on the endometrium
PRMs have been recently introduced in the clinical man-
agement of premenopausal women due to their powerful 
progesterone antagonist action. However, this could result 
in unopposed estrogen stimulation, increasing the risk of 
hyperplasia and endometrioid carcinoma. These observa-
tions inspired a workshop held in Bethesda in April 2006. 
The workshop, entitled Progesterone Receptor Modulators 
and the Endometrium, dealt with the long-term safety of 
treatment and the endometrial changes induced by PRM. 
After examining the biopsies from women included in four 
clinical trials with different PRMs (mifepristone, CDB2914, 
JNJ 17072341, and asoprisnil), a group of experts defined 
a common terminology and introduced specific recom-
mendations for pathologists.25 Various endometrial findings 
were described, but they did not include malignant and pre-
malignant changes. Some endometrial patterns resembled 
those observed during a normal endometrial cycle or other 
benign conditions, but some were unclassifiable on the basis 
of the available criteria and were designated PRM-associated 
endometrial changes (PAECs).
Some of the endometrial aspects reported in PAECs are 
induced by hormonal depletion as well as estrogen or pro-
gesterone stimulation. Most of the glands appear tubular, 
with rare coiling, and are surrounded by compact stroma 
that does not display any evidence of stromal breakdown. 
Glands are lined by low columnar to cuboidal epithelium 
showing varying degrees of secretory activity and ciliated 
metaplasia; scattered mitoses and apoptosis have been noticed 
even in individual glands. Cystic glands are common and 
may be numerous and confluent with flaccid walls. The 
stroma varies from fibrous to composed of plumped cells, 
without any evidence of predecidual change. Moreover, it 
shows a specific vascular pattern characterized by a network 
of capillaries in a chicken wire pattern and dispersed thick 
walled vessels. Occasional dilated vessels with prominent 
endothelium may be seen, but no evidence of fibrin thrombi 
has been reported.25
The endometrial biopsies taken in PEARL I and PEARL II 
allowed a detailed description of the endometrial effects of 
UPA (Table 2). The histologic features induced by UPA were 
compared to those detected in two control groups (women 
treated with placebo and patients receiving LA, respectively) 
at three different time points: at screening, at 3 months of 
Table 2 Adequacy of biopsies, observed lesions, non-physiological tissue, extensive cyst formation, and endometrium thickness .16 mm 
at screening and after 13 and 38 weeks (data from two Phase III studies, PEARL I and II)22,23,26
PEARL I PEARL II
Placebo 
(n=48)
UPA 5 mg 
(n=95)
UPA 10 mg 
(n=98)
UPA 5 mg 
(n=97)
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Abbreviations: GnRHa, leuprolide; H, hyperplasia; P, polyp; UPA, ulipristal acetate.





treatment and at 38 weeks, after treatment discontinuation. 
Polyps occurred in four UPA-treated women versus two 
patients receiving placebo and two being administered 
GnRHa; hyperplasia without atypia was detected only in one 
patient receiving 5 mg of UPA, after 3 months of treatment.26 
PAECs were found in 59.7% and 54.5% women treated with 
5 mg of UPA. Furthermore, PAECs were reported in 56.4% 
and 61.3% women treated with 10 mg in PEARL I and II, 
respectively. Such characteristics regressed in week 13, after 
discontinuation of treatment, and their incidence was com-
parable to the one reported in the placebo and in the GnRHa 
group. Extensive cyst formation was observed in one third of 
the women treated with UPA and in ,1% of women belong-
ing to the placebo group. Among PRM-specific endometrial 
changes, extensive cyst formation is quite peculiar, but it 
may be confused with disordered proliferative endometrium 
or simple, non-atypical endometrial hyperplasia arising from 
unopposed estrogen effect. However, the endometrial features 
of the afore mentioned pathologic conditions differ from 
PAEC in UPA-treated patients, and include:
1. low mitotic activity in both glands and stroma;
2. abortive sub-nuclear vacuoles;
3. apoptosis;
4. absence of stromal breakdown and glandular crowding.
The typical changes induced by unopposed estrogen are 
not detected with SPRM. The explanation of this paradoxi-
cal mechanism is still obscure. In addition to that, a slight 
increase in the mean endometrial thickness of treated patients 
has been observed radiologically. In PEARL I and PEARL II 
studies, endometrial thickness exceeding 16 mm was reported 
in 3%–5% cases at baseline and in up to 10%–15% cases 
after 3 months of UPA administration. This phenomenon 
spontaneously regressed after discontinuation of treatment 
(week 17).26–30
Discussion
Nowadays, no currently validated medical treatment causes 
fibroid elimination and hence surgery still represents the 
most effective treatment for symptomatic fibroids. The 
surgical approach and the type of surgery depends on 
several factors, including the severity of the symptoms, 
the volume of the fibroids, the size of the uterus, and the 
patient’s age. In several cases, hysterectomy is the treatment 
of choice, even though it causes infertility in reproductive 
age women.31
Selected cases of patients with small uterine fibroids 
who wish to preserve fertility can be administered a 
pharmacological symptomatic therapy. To date, GnRH 
analogues were the only drugs available for the preopera-
tive treatment of fibroids. Their use could be limited by 
several factors:
1. the control of bleeding is clinically relevant only after 
three months of therapy;
2. GnRHa are administered by injection, thereby limiting 
patient compliance;
3. the deep suppression of estrogen levels induces post-
menopausal symptoms (hot flushes, mood swings, bone 
density loss);
4. after drug withdrawal fibroids slowly go back to pre-
treatment size.13,32–34
UPA may be a new, effective, and well-tolerated option for 
the preoperative control of moderate and severe symptoms 
in reproductive age women with uterine fibroids. So far, 
the available studies dealing with 3-months-long UPA 
administration yielded the following results:22,23
•	 UPA rapidly controls uterine bleeding, acting faster than 
LA, while keeping the same effectiveness;
•	 the significant reduction in fibroid size allowed by UPA is 
maintained for at least 6 months after treatment withdrawal. 
This time interval is longer than reported for leuprolide;
•	 UPA significantly improves hemoglobin and hematocrit 
levels in anemic patients, and it is associated with better 
pain control and higher quality of life;
•	 when compared to LA, UPA shows a better tolerability 
profile: in fact, estradiol levels are kept within the normal 
range, and studies report fewer hot flushes and no impact 
on bone turnover.
The preoperative treatment with UPA might be useful for 
several clinical conditions. Firstly, it could be administered to 
patients waiting for surgery in order to achieve clinical control 
of the symptoms (in particular it could prevent the worsen-
ing of anemia) and possibly making surgery less invasive. 
Additionally, one should also consider that the reduction 
in uterine fibroid size lasts longer when UPA is adminis-
tered. This property appears advantageous when surgery is 
postponed after 3 months of pre-treatment. Furthermore, 
beneficial effects are not limited to the long-term. In fact, 
UPA has been proven to rapidly control bleeding and to 
restore hemoglobin and hematocrit levels quickly. These 
benefits could be exploited when surgery must be performed 
before the time scheduled and in the case of anemic patients 
in general. Finally, UPA may be a good option for women 
seeking pregnancy, for several reasons; in fertile women, 
UPA can grant an asymptomatic window in which sexual 
intercourse should be targeted to allow spontaneous concep-
tion. Moreover, UPA effectively reduces the invasiveness of 
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surgery, thereby preserving a woman’s fertility and improving 
obstetric outcomes (reduced risk of uterine rupture and need of 
cesarean section). Infertile patients, and also in vitro fertiliza-
tion (IVF) candidates, would benefit from UPA administration, 
as it allows for postponing surgery after childbearing.
Another interesting category includes pre-menopausal 
women, in whom UPA could control the symptoms until the 
onset of spontaneous menopause and avoid hysterectomy. 
Besides, when a prolonged treatment is required, the post-
menopausal symptoms are more frequent with LA than 
with UPA.11
Besides being advantageous in specific patient catego-
ries, UPA allows optimization of surgical interventions and 
facilitates the scheduling of surgery rooms. In fact, UPA 
pre-surgical treatment could reduce emergency surgery, allow 
a better outpatient management, and streamline the waiting 
list for surgery.
A finding of potential clinical interest is the occurrence 
of endometrial changes (PAECs) in patients receiving UPA. 
Endometrium treated with short term UPA shows reversible 
changes, which are included in the range of histologic altera-
tions induced by SPRMs in general. These endometrial changes 
are known as PAEC, and the major ones are the development 
of cystic changes and the increase in endometrial thickness.
Since the endometrial thickness is restored to baseline 
levels after treatment discontinuation, PAECs are considered 
a reversible pharmacodynamic response to the administra-
tion of UPA in most situations. In order to avoid unnecessary 
investigations and treatment, these specific changes should 
not be confused with disordered proliferative endometrium, 
unopposed estrogen effect, or endometrial hyperplasia.
UPA differs from the other available medical treatments 
for uterine fibroids (LA) in terms of both mechanism of 
action and route of administration (oral versus injectable), 
but it is equally effective for treating bleeding and myoma 
size reduction.34 Moreover, it has faster acting and more 
prolonged effects, along with a better tolerability and safety 
profile. However, further studies are needed to investigate 
some issues that are presently unclear, including: the entire 
mechanism of action, the effect of UPA on the endometrial 
vascularization, its influence on the choice of the type of 
surgery, as well as the possibility to avoid it completely, 
and finally the drug safety when pregnancy occurs after 
treatment. On the other hand, studies assessing the efficacy 
of UPA as a long-term treatment for uterine fibroids are 
ongoing.
In conclusion, UPA 5 mg/day for 3 months may be a 
good option for patients with symptomatic uterine fibroids 
in order to plan a treatment strategy tailored to meet patients’ 
individual needs.
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